Yuanfei Shi
- Cancer Research top 10%
-
- Protein Degradation and Inhibitors 3
- Histone Deacetylase Inhibitors Research 3
-
- Acute Myeloid Leukemia Research 8
- Multiple Myeloma Research and Treatments 3
- Chronic Myeloid Leukemia Treatments 3
-
- CAR-T cell therapy research 4
-
- Lymphoma Diagnosis and Treatment 10
-
- Chronic Lymphocytic Leukemia Research 5
- Journals
- Blood (1 paper)Experimental Cell Research (2 papers)European Journal of Pharmacology (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Yuanfei Shi
24 papers receiving 487 citations
Peers
Comparison fields: 5 of 66
- Cancer Research 160
- Molecular Biology 375
- Hematology 53
- Oncology 97
- Pathology and Forensic Medicine 43
Countries citing papers authored by Yuanfei Shi
This map shows the geographic impact of Yuanfei Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanfei Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanfei Shi more than expected).
Fields of papers citing papers by Yuanfei Shi
This network shows the impact of papers produced by Yuanfei Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanfei Shi. The network helps show where Yuanfei Shi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yuanfei Shi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 14 | |
| 3 | 2024 | 7 | |
| 4 | 2023 | 3 | |
| 5 | 2022 | 7 | |
| 6 | 2022 | 3 | |
| 7 | 2022 | 0 | |
| 8 | 2022 | 4 | |
| 9 | 2021 | 4 | |
| 10 | 2021 | 5 | |
| 11 | 2021 | 13 | |
| 12 | 2021 | 1 | |
| 13 | 2020 | 16 | |
| 14 | 2020 | 37 | |
| 15 | 2020 | 21 | |
| 16 | 2020 | 233 | |
| 17 | 2019 | 8 | |
| 18 | 2019 | 38 | |
| 19 | 2018 | 7 | |
| 20 | 2018 | 25 |
About Yuanfei Shi
Yuanfei Shi is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 26 papers that have together received 488 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (10 papers), Acute Myeloid Leukemia Research (8 papers), Chronic Lymphocytic Leukemia Research (5 papers), CAR-T cell therapy research (4 papers), Multiple Myeloma Research and Treatments (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), Protein Degradation and Inhibitors (3 papers) and Histone Deacetylase Inhibitors Research (3 papers). The work is most often cited by research in Cancer Research (160 citations), Molecular Biology (375 citations) and Hematology (53 citations). Yuanfei Shi has collaborated with scholars based in China and United States. Frequent co-authors include Huafei Shen, Wanzhuo Xie, Yanchun Zhao, Zhihong Fang, Jie Jin, Manman Deng, Bing Xu, Jie Zha, Xiujin Ye and Jing Ye. Their work appears in journals such as Blood, Experimental Cell Research and European Journal of Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.